Disease · MONDO_0004669

salivary gland cancer

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. salivary gland cancer. Diseases, record MONDO_0004669. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004669

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: salivary gland cancer; Open Targets
Open Targets ID: MONDO_0004669; Open Targets
Other names: cancer of saliva-secreting gland, cancer of salivary gland, cancer of the salivary gland, malignant neoplasm of saliva-secreting gland, malignant neoplasm of salivary gland, malignant neoplasm of salivary gland duct, malignant neoplasm of the salivary gland, malignant saliva-secreting gland neoplasm, malignant salivary gland neoplasm, malignant salivary gland tumor, malignant salivary gland tumour, malignant tumor of salivary gland, malignant tumor of the salivary gland, malignant tumour of salivary gland, malignant tumour of the salivary gland, saliva-secreting gland cancer; Open Targets
Disease Ontology: DOID:8850; Disease Ontology
MeSH: D012468; MeSH
NCI Thesaurus: C3811; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 36 of its 40 drugs, from ClinicalTrials.gov; Open Targets

Drugs40

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 2	ClinicalTrials.gov	4	4	3	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
TRASTUZUMAB	CHEMBL1201585	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
BICALUTAMIDE	CHEMBL409	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 40

See all 40 drugs

Targets72

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ERBB2	Receptor tyrosine-protein kinase erbB-2	6	Receptor protein-tyrosine kinase erbB-2 binding agent; Receptor protein-tyrosine kinase erbB-2 inhibitor	Phase 2	https://conductscience.org/library/genes/2064	Drugs and targets
EGFR	Epidermal growth factor receptor	4	Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
PDCD1	Programmed cell death protein 1	4	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
TUBA1A	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/203068	Drugs and targets

1 to 10 of 72

See all 72 targets

Trials34

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02564900	Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors	Phase 1	292	2021-06-23	Advanced Solid Tumors	TRASTUZUMAB DERUXTECAN	Its record names the disease	ClinicalTrials.gov
NCT03172624	Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer	Phase 2	64	2025-12-18	Salivary Gland Cancer	IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT00859937	Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors	Phase 2	55	2015-04-03	Malignant Salivary Gland Neoplasm, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v7	DASATINIB ANHYDROUS	Its record names the disease	ClinicalTrials.gov
NCT02538510	Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery	Phase 1/2	50	2020-10-22	Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Salivary Gland Carcinoma, Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary, Stage III Major Salivary Gland Carcinoma, Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage III Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma, Stage IVA Major Salivary Gland Carcinoma, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVB Major Salivary Gland Carcinoma, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVC Major Salivary Gland Carcinoma, Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma	PEMBROLIZUMAB, VORINOSTAT	Its record names the disease	ClinicalTrials.gov
NCT02749903	Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers	Phase 2	46	2020-01-13	Androgen Receptor Positive, Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Salivary Duct Carcinoma, Salivary Gland Adenocarcinoma, NOS, Salivary Gland Basal Cell Adenocarcinoma, Stage III Major Salivary Gland Cancer AJCC v7	ENZALUTAMIDE	Its record names the disease	ClinicalTrials.gov
NCT00095563	Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers	Phase 2	40	2017-04-18	High-grade Salivary Gland Carcinoma, High-grade Salivary Gland Mucoepidermoid Carcinoma, Low-grade Salivary Gland Carcinoma, Low-grade Salivary Gland Mucoepidermoid Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Salivary Gland Acinic Cell Tumor, Salivary Gland Adenocarcinoma, Salivary Gland Adenoid Cystic Carcinoma, Salivary Gland Malignant Mixed Cell Type Tumor	LAPATINIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT00509002	Iressa Study in Patients With Salivary Gland Cancer	Phase 2	37	2017-11-24	Salivary Gland Cancer	GEFITINIB	Its record names the disease	ClinicalTrials.gov
NCT01613768	Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer	Phase 2	29	2018-08-10	Recurrent Salivary Gland Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer	ERIBULIN	Its record names the disease	ClinicalTrials.gov
NCT03749460	Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers	Phase 1/2	20	2023-12-29	Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lung, Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IVA Major Salivary Gland Cancer AJCC v8, Stage IVB Major Salivary Gland Cancer AJCC v8, Stage IVC Major Salivary Gland Cancer AJCC v8	IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT06581432	Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations	Phase 2	588		Solid Tumours	ZONGERTINIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 34

See all 34 trials

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
R/M Adenoid Cystic Carcinoma (ACC) vs R/M SGC of Any Histology, Except ACC (Non ACC): deaths from any cause	6 of 32	7 of 32	64	NCT03172624	Trial comparisons
R/M Adenoid Cystic Carcinoma (ACC) vs R/M SGC of Any Histology, Except ACC (Non ACC): serious adverse events	18 of 32	9 of 32	64	NCT03172624	Trial comparisons
Adenoid Cystic Carcinoma vs Non Adenoid Cystic Carcinoma: serious adverse events	12 of 40	8 of 14	54	NCT00859937	Trial comparisons
Head and Neck Squamous Cell Carcinoma vs Salivary Gland Carcinoma: deaths from any cause	22 of 25	23 of 25	50	NCT02538510	Trial comparisons
Head and Neck Squamous Cell Carcinoma vs Salivary Gland Carcinoma: serious adverse events	1 of 25	1 of 25	50	NCT02538510	Trial comparisons

Papers from its trials22

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32213540	RESULT	1	PubMed
31825192	RESULT	1	PubMed
31047804	RESULT	1	PubMed
31047803	RESULT	1	PubMed
29037983	RESULT	1	PubMed
19924794	RESULT	1	PubMed
16470745	RESULT	1	PubMed
41777164	DERIVED	1	PubMed
41213241	DERIVED	1	PubMed
38231777	DERIVED	1	PubMed

1 to 10 of 22

See all 22 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004669

GET https://conductscience.org/api/diseases/v1/MONDO_0004669/drugs?page=2

API reference For AI assistants